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Abstract
Background—The Patient-Reported Outcomes Measurement Information System® (PROMIS®) 
created pediatric self-report scales measuring a variety of health attributes (domains), but their 
responsiveness to changes in health status has not yet been determined in children with sickle cell 
disease (SCD).
Procedure—A convenience cohort of symptomatic SCD children, aged 8-17 years, were asked 
to complete PROMIS pediatric scales at an initial clinic visit, at the end of a subsequent 
hospitalization for sickle pain, at a subsequent clinic visit or at home 2-3 weeks after 
hospitalization, and at a clinic visit 1-2 years after their initial assessment.
Results—A total of 121 participants (mean age 12.5 ± 3.1 years, 56.2% female) participated in 
the study. Pain interference and fatigue domain scores were elevated at baseline, increased 
substantially during hospitalization, and largely returned to baseline by the recovery period, while 
the depressive symptoms, anger, and anxiety domain scores displayed a less pronounced elevation 
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during hospitalizations and a slower return to baseline levels. The two physical functioning scales 
showed a substantial decline in response to hospitalization, but only modest improvements at the 
recovery assessment, likely representing incomplete recovery.
Conclusions—Several PROMIS Pediatric measures were responsive to changes in health status 
associated with occurrence and resolution of acute vaso-occlusive pain requiring hospitalization. 
The substantial differences in these domains during SCD-related pain exacerbations support their 
potential usefulness in clinical research or in clinical practice. Further studies to characterize 
variations in symptom patterns over time may provide insights into strategies for more effective 
management of sickle pain.
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Introduction
Measures of health-related quality of life (HRQOL) are being increasingly used to assess the 
impact of treatment in clinical trials [1] and in clinical practice settings. [2] These measures 
of patient-reported outcomes (PROs) provide an important additional perspective on the 
impact of treatment effects or disease manifestations. Such measures may be particularly 
useful in chronic conditions with complex symptomatology that lack surrogate biomarkers 
to assess clinical outcomes, such as sickle cell disease (SCD).
The Patient-Reported Outcomes Measurement Information System® (PROMIS®; 
www.nihpromis.org) developed pediatric self-report scales to provide valid and reliable 
assessment of HRQOL domains for children. [3] The PROMIS measures were developed 
through an extensive review of the literature, expert review, and qualitative methods (focus 
groups and cognitive interviewing), [4-6] consistent with the FDA guidance on the 
development of such measures. [7] Subsequent quantitative analyses utilized item response 
theory (IRT) to develop item banks on a common HRQOL metric suitable for computer 
adaptive testing (CAT; fixed-length short forms were also developed as alternative modes of 
administration). [3] These measures were normed in a diverse sample of children and 
adolescents [8] and have been validated in several chronic childhood conditions and 
diseases. [9-13]
A number of generic HRQOL measures have been examined in children with SCD, 
including the Child Health Questionnaire (CHQ), the Peds QL ver 4.0™, and the PROMIS 
pediatric measures. [14] The Peds QL generic version has demonstrated significant 
reliability, and construct and discriminant validity in cross-sectional studies, [15,16] as have 
the PROMIS pediatric measures. [17] The Peds QL is also now available in a SCD-specific 
measure, [18,19] and clinically meaningful scale score ranges have been validated for use in 
clinical practice. [20] However, evidence of the responsiveness of any of these measures 
over time is limited.
A responsive measure is sensitive to improvements, deteriorations, and stability of health 
status over time, and assessing responsiveness is an important component of establishing 
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validity. [21] A longitudinal study of patients undergoing treatment or experiencing 
exacerbations or remissions of their disorder is usually required for such evaluations. For 
example, the responsiveness of the PROMIS adult physical function measure (PF-20) has 
been evaluated in patients participating in the Arthritis, Rheumatism and Aging Medical 
Information Systems (ARAMIS) observational cohorts. [22] The PROMIS PF-20 was more 
responsive than two widely used (‘legacy’) measures, the SF-36 and the Health Assessment 
Questionnaire (HAQ).
As part of a larger study of the responsiveness of the PROMIS pediatric measures to changes 
in health status in childhood illnesses, including cancer, kidney disease, and asthma, we 
evaluated the responsiveness of selected PROMIS pediatric measures in a sample of children 
and adolescents with SCD. We studied children ages 8- to 17-years old during two routine, 
non-acute healthcare encounters over a 1-2 year interval; during an illness exacerbation 
(hospitalization for treatment of severe vaso-occlusive pain); and after a subsequent recovery 
period of several weeks. Based on previous studies of children [23] and adults, [24] levels of 
pain interference and fatigue were expected to increase with disease exacerbations (SCD 
pain episodes) and then decline to baseline levels upon recovery, while levels of physical 
functioning were expected to decline during disease exacerbations and improve upon 
recovery. Anxiety, depressive symptoms, anger, and peer relationship scores were expected 
to remain largely unchanged.
Methods
Recruitment
A convenience sample of SCD patients aged 8-17 years was recruited from 3 clinical sites in 
a large sickle cell program (Children's Healthcare of Atlanta). Only those children with one 
or more acute care visits for pain in the previous year were eligible, as we intended to assess 
both their usual state of health and an episode of severe pain, and thus excluded 
asymptomatic individuals. Eligible children and their parent/guardian also had to be able to 
read and speak English, possess functional computer skills (defined as the ability to see and 
interact with a computer screen, keyboard, and mouse), and be willing to give written assent/
permission for study participation. Excluded were children and adolescents who had any 
concurrent medical or psychiatric condition that precluded study participation, or cognitive 
or other impairments (e.g., visual) that interfered with completing a self-administered 
computer-based questionnaire.
Data collection
After consent/assent was obtained by study staff, parents completed the demographic and 
SCD-related medical history items on the computer and then children completed the 
pediatric PROMIS measures. These assessments were completed at an initial routine 
healthcare encounter in the sickle cell clinic (baseline) and at a subsequent routine clinic 
visit one to two years later (follow-up). These measures were repeated prior to discharge 
from a subsequent hospitalization for pain (pain hospitalization) and after a subsequent 
recovery period of several weeks (recovery). Additional participants were enrolled during a 
pain hospitalization without a previous baseline clinic visit to facilitate completion of further 
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hospitalization and recovery assessments. All pain hospitalization assessments were 
administered at the end of the hospitalization (on the day of discharge) when pain is 
typically well controlled.
Using a laptop or tablet in a private clinic exam room, a nearby conference/consultation 
room, or in their private hospital room, participants accessed the survey using Assessment 
Center (http://assessmentcenter.net/) via the Internet and completed the measures. Parents 
were invited to remain with their child if they preferred; however, if they remained, they 
were asked not to assist their child with responding and instead allow the study team 
member who remained in the room to assist if needed. To accommodate some families who 
were unable to return to clinic for hospital follow-up visits, paper versions (fixed short 
forms) of the PROMIS measures were sent to their homes and returned by mail. Children or 
adolescents received a $10.00 gift card for participating in each assessment.
Assenting children and adolescents were assigned unique identification numbers using a 
computer-based system. No other identifiers were collected by the computerized assessment. 
Only de-identified data were used in the analyses.
Measures
Parents completed a 16-item demographic form and a 17-item form detailing their child's 
SCD treatment, occurrence of chronic complications, frequency of acute complications, and 
the presence of pain experienced by their child during the previous 7 days. Medical 
information was verified, as needed, from medical records.
Eight PROMIS pediatric measures (Physical Functioning-Mobility, Physical Functioning-
Upper Extremity, Pain Interference, Fatigue, Depressive Symptoms, Anxiety, Peer 
Relationships, and Anger) were administered. These measures elicited responses based on 
the previous 7 days using a 5-point response option ranging from “with no trouble” to “not 
able to do” for physical functioning measures and from “never” to “almost always” for other 
measures. Higher scores indicate more of the measured domain being assessed, which 
signifies worse HRQOL for depressive symptoms, anxiety, anger, fatigue, and pain 
interference, and better HRQOL for mobility, upper extremity functioning, and peer 
relationships. PROMIS pediatric measures are scored on a T-score metric, with a mean of 50 
and a standard deviation of 10 based on the original reference sample of children and 
adolescents. [22]
These and other PROMIS pediatric measures are available at no cost for download at 
www.nihpromis.org or www.healthmeasures.net after a simple registration process. These 
websites also provide the characteristics of the measures, which are also available in 
associated publications. [23-28] Guidance for their use and scoring as fixed short forms or as 
computer adapted tests are available at these websites, as well as at 
www.assessmentcenter.net, which provides a software platform for administration and 
scoring as used in our study.
Children and adolescents also completed Global Ratings of Change (GRC) assessments for 
overall health, pain, fatigue, physical function, peer relationships, and anxiety as an anchor 
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for establishing differences. Response format was better, worse, or the same. The GRC was 
administered at the pain recovery visit with reference to the preceding pain episode. The 
relatively short time frame between the hospitalized pain event and the recovery visits was 
expected to enhance the reliability of this response.
Statistical Analysis
All statistical analyses were produced via SAS version 9.3 and R version 3.1.1. [25,26] 
Descriptive statistics for each of the PROMIS domains were analyzed in tabular and 
graphical form. Mean values and corresponding standard errors were considered, in addition 
to the number of non-missing data points at each of the four possible assessments. Paired t-
tests were used to compare subjects who had non-missing observations in each of the 
episodes considered. Alternately, a generalized linear model (GLM) with an identity link 
function and compound symmetric correlation structure was applied to jointly model the 
continuous outcomes for the four assessments for all subjects. [27] This technique is a 
generalization of ANOVA with unequal sample sizes with correlated outcomes. Missing data 
were assumed to be missing completely at random.
To further describe the marginal modelling approach, Let Yi denote the observation vector of 
length ni for participant i (1≤ ni ≤ 4), where i = 1, ..., 121. The model is written as Yi = Xi β 
+ ei, where ei follows a multivariate normal distribution of dimension ni with mean zero and 
covariance ϭ2V, where V is the (compound symmetric) population correlation matrix. The 
vector β=(μB, μP, μR, μA) contains the four unknown mean parameters, Baseline, Pain Event, 
Recovery, and Follow-up Visit, while the matrix Xi is a 4 × 4 identity matrix for subject i. 
Generalized estimating equations (GEE) were applied to estimate β and correlation 
parameters. Table II gives the estimates and standard errors of the domain marginal means 
for each assessment. Table III gives the estimates and p-values for differences between the 
selected means using the GLM. The test of the difference between two means using the 
GLM for repeated measures generalizes the paired t-test by using all observations from each 
participant (even if the participant had only one value) and also adjusting for the correlation 
between observations.
Results
Enrollment of Study Participants
Over a 20-month period from May 2011 to January 2013, a convenience sample of 121 
children and adolescents were recruited. Of these, 91 (75%) were initially recruited at a 
routine clinic healthcare encounter while 30 (25%) were recruited during hospitalizations for 
pain management (Figure 1). Seventy individuals recruited in clinic and 9 recruited during 
hospitalizations provided an additional assessment, either in person or by mail, at a 
subsequent routine clinic visit at an interval of 1.5 ± 0.56 years.
Twenty one of the 91 individuals recruited at a routine clinic healthcare encounter completed 
an assessment at the end of a subsequent hospitalization (16.6 ± 19.1 months from baseline 
visit), with 16 (76%) of those completing hospitalization assessments also completed pain 
recovery visits at a median interval of 20 days (range 7-67 days) from their hospitalization 
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assessment. Recovery assessments were completed by 16 (53%) of participants enrolled at 
hospitalizations, which occurred at a median interval of 13 days (range 7-29 days) after the 
completion of hospitalization assessments.
Sample Characteristics
The 121 participants were equally represented in the 8-12 and 13-17 year old age groups 
(mean age 12.5 ± 3.1 years, 56.2% female). Almost all participants were self-identified by 
parents/guardians as African American and not of Hispanic ethnicity (Table I). Most 
participants had a homozygous S (SS) or Sickle B0 thalassemia phenotype (73.6%), while 
24.8% had SC or Sickle B+thalassemia phenotypes. Children prescribed hydroxyurea (60% 
of those participants with SS or SB0thalassemia) had been prescribed this medication for at 
least 6 months prior to their initial PROMIS assessment.
Additional medical comorbidities were not uncommon with 52% reporting one or more co-
occurring conditions at their baseline visit (Table I), the most common of which was a 
physician diagnosis of asthma. A recent hip or other joint problem that interfered with usual 
activities at the baseline visit was reported for 14% of participants, and 41% reported pain in 
the week prior to their baseline assessment.
PROMIS measures
At the initial baseline clinic visit, the pain interference mean score (55.9) was substantially 
above, while the fatigue mean score (52.1) was modestly above those of the original 
PROMIS reference sample norms with mean 50 (Table II), reflecting the prevalence of pain 
in this symptomatic SCD sample. As expected, mobility and peer relationships were 
somewhat below the reference sample averages, reflecting mild impairment from this 
chronic disease, while upper extremity physical function was similar to that of the reference 
sample. Interestingly, anger, anxiety, and depressive symptoms domain scores were lower 
than reference sample averages. The reference sample, which was used to calibrate the 
PROMIS pediatric item banks used in this study, comprised a diverse mix of children and 
adolescents, many of whom had health conditions; as a result, scores on the PROMIS 
measures do not reflect normative population scores. [8]
Responsiveness
Baseline clinic visit to annual follow-up visit comparisons
In general, PROMIS domain scores at the annual follow-up period were similar to those 
from the baseline, consistent with the absence of any major changes in therapy (Table II). 
The differences in comparison to baseline values were relatively small (1-2 points) for all 
domains and not statistically significant (Table III). The length of time between assessments 
(mean 1.5 years, range 0.65-2.74 years) was not significant when added as an additional 
variable in these marginal models. This suggests considerable stability in these domain 
scores over a modest period of time in the absence of major changes in symptom burden or 
treatment.
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Initial clinic visit to pain hospitalization comparisons
As expected, given that these individuals were admitted for management of severe pain, pain 
interference and fatigue mean scores were substantially higher during pain episode 
hospitalizations (Table II), with large statistically significant differences (p<0.001) in 
comparison to scores from the initial clinic visits (Table III). These differences could be 
considered to be clinically significant as they were associated with hospitalization. Scores 
for depressive symptoms and anxiety had similar increases during the pain hospitalizations, 
which were also statistically significant. A comparable relationship was observed for the two 
physical functioning domains, reflecting impaired functioning during hospitalization with 
similar statistically significant differences in comparison to the initial clinic visit.
Pain hospitalization to recovery comparisons
As these individuals were admitted for management of severe pain, it was expected that the 
pain interference and fatigue domain scores would be high, reflecting the impact of the 
previous days of severe pain and its treatment, while scores would be lower at the recovery 
assessment, reflecting improvement in pain. As predicted, when compared to their prior 
hospitalization using the GRC, most participants reported at their recovery assessment that 
their overall health and pain were better (Table IV), with somewhat fewer reporting similar 
improvements in fatigue and physical activity, while anxiety and peer relationships were 
more likely to be reported as unchanged. Consistent with these global ratings of change, 
statistically significant improvements were noted for pain interference and fatigue scores 
using the GLM procedure comparing pain to recovery assessments (Table III). These 
changes remained statistically significant when only subjects with paired results were 
compared. Scores for depressive symptoms, anger, and anxiety improved (decreasing scores) 
comparing end of hospitalization to recovery assessments. Difference in depressive 
symptoms scores was statistically significant using the GLM procedure, but not when 
comparing paired data, likely reflecting the loss of power from the smaller sample size. A 
similar relationship was observed for the two physical functioning domains reflecting 
impaired functioning during hospitalization and increasing (improving) functioning by the 
time of the recovery assessment, but this difference was modest and not statistically 
significant. The length of time between assessments (mean 21.5 days, range 6-92 days) was 
not significant when added as an additional variable in these marginal models.
Responsiveness patterns
Of interest, a comparison of the hospitalization and recovery assessments to those at the 
baseline or follow-up assessments (Figure 2) suggest several different patterns of change for 
the PROMIS domain scores. Pain interference and fatigue domain scores were elevated at 
baseline, increased substantially during hospitalization, and largely returned to baseline by 
the recovery period (Figure 2A). Compared to pain interference and fatigue scores, the 
mental health-related domains of depressive symptoms, anger, and anxiety displayed a less 
pronounced elevation during hospitalizations and a slower return to baseline (Figure 2B). 
While showing a robust change (decline in functioning) in response to hospitalization 
similar to pain interference, the two physical functioning domains showed only a modest 
improvement at the recovery assessment, likely representing a slow or incomplete recovery 
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of physical activity (Figure 2C). In contrast, peer relationship domain scores were relatively 
unchanged at each of the assessment points (Figure 2D).
Discussion
We experienced a number of challenges conducting this study that may be relevant to future 
studies. Measure completion was excellent when supervised by study staff in the clinical 
care setting using provided laptops/tablets for accessing the study website over the hospital 
wireless internet access system. For a number of reasons, some children were unable to 
return for follow-up clinic visits and their completion of recovery assessments was limited. 
Those participants unable to return to clinic were encouraged to complete the measures over 
the internet using the study website. However, completion rates improved when PROMIS 
pediatric short forms in paper format where mailed to homes suggesting that some children/
families in our sample had limited computer resources or internet access at home, or found 
our study website difficult to use without assistance. Determining subject preferences for 
assessment response format at study entry might improve response rates. [28] Our interest in 
validating the available PROMIS pediatric domains in SCD required a modest participant 
burden (about 20-30 minutes to complete measures) that could be reduced in future studies 
by targeting measures to specific research or clinical questions being evaluated, or by using 
the shorter PROMIS pediatric profiles, which were not available at the time this study was 
conducted.
Our results continue to demonstrate the substantial impact of pain on numerous aspects of 
the lives of children and adolescents with SCD. Acute SCD pain sufficiently severe as to 
require hospitalization, was associated with increased levels of fatigue and deleterious 
consequences on depressive symptoms and physical functioning, similar to that reported 
using the PROMIS measures in adults with SCD, [29] or chronic noncancer pain disorders. 
[30] These results with the PROMIS pediatric measures were congruent with the literature 
that examined other symptom measurement scales, such as the Brief Pain Inventory in adults 
with SCD, [24] and the M. D. Anderson Symptom Inventory (MDASI) in adults with cancer 
pain. [31]
The large magnitude of changes for fatigue may reflect not only the impact of pain intensity 
on fatigue during hospitalization, but also the impact of worsening anemia typical of this 
disease exacerbation, and the sedating effects of intravenous opioids typically used for pain 
management in that setting. The rapid improvement in pain and fatigue scores following 
hospitalization with slower improvement in physical functioning scores suggests that 
different symptoms and various aspects of functioning may have different patterns of 
recovery following hospitalization.
In comparison to baseline values, pain interference, fatigue, depressive symptoms, anxiety, 
and both physical functioning measures were sensitive to the important clinical changes in 
symptoms experienced during hospitalization for severe sickle cell pain. These differences 
were similar or above the level of change (2-3 points) that healthcare providers and parents/
children identified as recognizably different, often referred to as the minimally important 
difference (MID).[32] Not surprising in a clinical setting, we observed variability in 
intensity of symptoms and PROMIS pediatric domain responses among participants during 
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the various clinical encounters; further appropriately designed studies are needed with these 
measures in SCD clinical populations to confirm relationships between PROMIS pediatric 
scores and clinical severity, as has been done for the Peds QL [20], or that may signal the 
need for clinical intervention, such as depression. [33] Evolving efforts to provide closer 
integration of PRO instruments with electronic medical record systems would facilitate these 
types of studies.[34,35]
Limitations
There are a number of limitations to our study. Although our study sample was diverse in 
age, sex, and type of hemoglobinopathies, we did not have a probability sample and findings 
cannot be generalized to all patients with SCD. We only studied episodes of pain sufficiently 
severe to require hospitalization, so the sensitivity of these measures to symptom changes 
caused by milder pain managed at home has not been established. This study had a complex 
set of missing values; for simplicity of analyses, we assumed all missing values were 
missing completely at random. Also, the GLM models used did not account for individual or 
disease-related factors that may be correlated to these PRO scores, such as demographic or 
hematologic variables.
In future research, we plan to assess the effect of missing data and also study demographic 
and other clinical explanatory variables that may impact these PRO scores. Further studies of 
symptom recovery patterns or of symptoms preceding acute care visits may be facilitated by 
measures with enhanced sensitivity over shorter periods of time, such as using 24 hour recall 
periods to assess daily changes in pain and other symptoms. [36] Successful PRO studies 
will provide careful attention to minimizing participant burden, facilitate measure 
completion using optimal formats for the assessment event, and maximize integration with 
clinical care.
Conclusion
Children and adolescents with SCD hospitalized for pain management, the most common 
cause for hospitalization in pediatric SCD, experienced substantial worsening of several 
symptoms such as pain, fatigue, depression, and considerable impairment of physical 
functioning, which improved to variable degrees as they recovered at home. PROMIS 
Pediatric measures were responsive to these changes in acute vaso-occlusive pain, fatigue, 
and in physical and emotional functioning. The reports of substantial levels of fatigue in 
SCD in our study has also has been reported by others [37-39] and suggests the need for 
more attention to this potentially distressing symptom, as does the apparent slow recovery in 
physical functioning after hospital discharge. The magnitude of changes for many of these 
domains, particularly pain interference and fatigue, suggest the PROMIS measures’ potential 
usefulness in clinical trials of novel therapies for vaso-occlusion. Further studies may find a 
role in using PROMIS measures in clinical practice settings to monitor a patient's health 
status over time.
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A Fatigue ───, Pain Interference – – –; B Anger ••••, Anxiety – • – •, Depression – – –; 
C Lower Extremity Functioning (Mobility) – • – • –, Upper Extremity Functioning • – • – •; 
D Peer Relationships – – –
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Table I
Demographic and clinical characteristics of study participants (n=121)
Characteristic N (%) Mean (SD)
Age (in years) at earliest study visit
* 12.5 (3.1)
    8 – 12 59 (49.6)
    13 – 17 60 (50.4)
Gender
    Male 53 (43.8)
    Female 68 (56.2)
Race
    Black or African American 120 (99.2)
    Multiple races 1 (0.8)
Ethnicity
    Hispanic 3 (2.5)
    Non-Hispanic 118 (97.5)
Genotype
    SS or SB0thalassemia 89 (73.6)
    SC or SB+thalassemia 30 (24.8)
    Other 1 (1.6)
Hydroxyurea usage reported at initial assessment
^
    No 65 (55.1)
    Yes 53 (44.9)
Comorbidities reported at baseline visit
**
    None 43 (47.3)
    One other health problem 27 (29.7)
    Two or more health problems 21 (23.1)
Treated for pain at home in week prior to baseline visit
^
    No 52 (59.1)
    Yes 36 (40.9)
Hip or joint problems reported at baseline visit
^
    No 76 (86.4)




only available for 91 patients with baseline data
^
only available for 118 participants
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Table II









Pain interference 56.1 (1.2) 55.5 (1.1) 61.0 (1.2) 55.5 (2.1)
Fatigue 52.2 (1.5) 53.0 (1.5) 61.7 (1.8) 50.9 (2.6)
Depression 45.1 (1.1) 47.1 (1.1) 50.2 (1.2) 46.7 (1.6)
Anxiety 44.1 (1.3) 45.0 (1.1) 49.1 (1.5) 46.2 (1.8)
Anger 42.8 (1.3) 44.4 (1.3) 46.7 (1.5) 43.2 (2.2)
Mobility 48.2 (0.9) 47.1 (1.0) 41.5 (1.5) 43.8 (1.9)
Upper dexterity 50.0 (0.9) 48.2 (0.9) 43.1 (1.4) 45.3 (1.9)
Peer relationships 47.7 (1.2) 48.7 (0.8) 47.2 (1.3) 48.2 (1.4)
SE = Standard Errors
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Table III
Estimated mean differences in PROMIS domain scores between assessments
Domain Baseline Visit to Follow-up Visit 
(SE)
Baseline Visit to Hospital Episode 
(SE)
Hospital Episode to Recovery 
Episode (SE)






















Upper dexterity 1.8 (1.1)
−5.1 (1.6)
** 2.2 (2.2)
Peer relationships −1.0 (1.3) −1.4 (1.3) 1.0 (1.5)
The direction of the sign of the estimated mean difference indicates the direction that the scores are changing over time. For example, a positive 
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Table IV









Health 29 (76.3) 4 (10.5) 3 (7.9) 2 (5.3)
Pain 27 (71.1) 5 (13.2) 4 (10.5) 2 (5.3)
Energy 25 (65.8) 8 (21.1) 3 (7.9) 2 (5.3)
Physical Activity 21 (55.3) 13 (34.2) 2 (5.3) 2 (5.3)
Worries 17 (44.7) 17 (44.7) 2 (5.3) 2 (5.3)
Friendships 15 (39.5) 20 (52.6) 1 (2.6) 2 (5.3)
Question was worded: “How is your ____ compared to your last study visit?”
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